Ribociclib for the firstline treatment of advanced hormone receptorpositive breast cancer a review of subgroup analyses from the MONALEESA2 trial
Bioportfolio,
Endocrine therapy is recommended for patients with hormone receptor-positive (HR+) advanced and metastatic breast cancer…